160 related articles for article (PubMed ID: 29979855)
21. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Ginsberg HN
Clin Cardiol; 1995 Jun; 18(6):307-15. PubMed ID: 7664504
[TBL] [Abstract][Full Text] [Related]
22. Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
Rodriguez F; Harrington RA
JAMA; 2016 Nov; 316(19):1967-1968. PubMed ID: 27838727
[No Abstract] [Full Text] [Related]
23. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
24. Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
Achimastos A; Alexandrides T; Alexopoulos D; Athyros V; Bargiota A; Bilianou E; Chrysochoou C; Drogari E; Elisaf M; Ganotakis E; Goudevenos I; Ioannidis I; Kolovou G; Kotsis V; Lekakis I; Liberopoulos E; Melidonis A; Nikolaou V; Ntaios G; Papanas N; Pappas S; Pitsavos C; Rallidis L; Richter D; Skoumas I; Tentolouris N; Tousoulis D; Tselepis A; Tsioufis K; Tziakas D; Tziomalos K; Vardas P; Vlachopoulos C; Vlahakos D
Hormones (Athens); 2016; 15(1):8-14. PubMed ID: 27086681
[TBL] [Abstract][Full Text] [Related]
25. The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.
Smith L; Mosley J; Yates J; Caswell L
J Pharm Pharm Sci; 2016; 19(1):137-46. PubMed ID: 27096698
[TBL] [Abstract][Full Text] [Related]
26. [Statin intolerance].
Tonstad S
Tidsskr Nor Laegeforen; 2017 Jan; 137(1):36-38. PubMed ID: 28073228
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of proprotein convertase subtilisin/kexin type 9 in the treatment of hypercholesterolemia.
Ascaso JF
Endocrinol Nutr; 2016; 63(6):255-7. PubMed ID: 27050861
[No Abstract] [Full Text] [Related]
28. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Cardiovasc Drugs Ther; 2016 Jun; 30(3):297-304. PubMed ID: 26936841
[TBL] [Abstract][Full Text] [Related]
29. [HMG-CoA reductase inhibitors].
Yamamoto A
Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
[No Abstract] [Full Text] [Related]
30. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
Tomiyama H; Doba N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
[No Abstract] [Full Text] [Related]
31. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
32. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
33. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition--The Dream of Translational Medicine.
Uppugunduri CR; George M
J Cardiovasc Pharmacol; 2016 Feb; 67(2):191-2. PubMed ID: 26398165
[No Abstract] [Full Text] [Related]
34. Needed: pragmatic clinical trials for statin-intolerant patients.
Maningat P; Breslow JL
N Engl J Med; 2011 Dec; 365(24):2250-1. PubMed ID: 22085320
[No Abstract] [Full Text] [Related]
35. [Not Available].
Bilz S
Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
[No Abstract] [Full Text] [Related]
36. Evolocumab: A Review in Hyperlipidemia.
Keating GM
Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308
[TBL] [Abstract][Full Text] [Related]
37. NICE recommends PCSK9 inhibitors for patients not responding to statins.
Mayor S
BMJ; 2016 May; 353():i2609. PubMed ID: 27159996
[No Abstract] [Full Text] [Related]
38. The efficacy advantage of evolocumab (AMG 145) dosed at 140mg every 2weeks versus 420mg every 4weeks in patients with hypercholesterolemia: Evidence from a meta-analysis.
He XX; Zhang R; Zuo PY; Liu YW; Zha XN; Shan SS; Liu CY
Eur J Intern Med; 2017 Mar; 38():52-60. PubMed ID: 28341307
[TBL] [Abstract][Full Text] [Related]
39. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of high blood cholesterol in patients with coronary heart disease].
Nagai Y; Yamashita S
Nihon Rinsho; 2003 Apr; 61 Suppl 4():675-81. PubMed ID: 12735049
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
